Unjha Formulations Ltd Upgraded to Sell on Technical and Valuation Improvements

Quality Assessment: A Mixed Fundamental Picture

Unjha Formulations operates within the Pharmaceuticals & Biotechnology sector, classified as a micro-cap with a current market price of ₹27.15, close to its 52-week high of ₹29.50. The company’s quality rating remains cautious due to its weak long-term fundamental strength. Over the past five years, operating profits have grown at a modest compound annual growth rate (CAGR) of 6.19%, signalling limited expansion in core earnings capacity.

Moreover, the company’s ability to service debt is under pressure, with an average EBIT to interest coverage ratio of just 0.43, indicating vulnerability to interest obligations. This weak debt servicing capacity weighs on the overall quality grade, despite a respectable return on capital employed (ROCE) of 40.91% and a return on equity (ROE) of 12.5%, which suggest efficient use of capital and moderate profitability for shareholders.

Financial results for Q1 FY26-27 were flat, reinforcing concerns about near-term growth momentum. However, the company’s long-term performance relative to the broader market remains impressive, with a 5-year return of 137.53% compared to the Sensex’s 43.97%, and a 3-year return exceeding 103% against the Sensex’s 19.57%. This outperformance highlights the stock’s resilience despite fundamental headwinds.

Valuation Shift: From Attractive to Fair

The valuation grade for Unjha Formulations has been downgraded from attractive to fair, reflecting a re-rating of the stock’s multiples in the context of its sector peers. The company currently trades at a price-to-earnings (PE) ratio of 25.34, which is moderate but elevated relative to some competitors in the Pharmaceuticals & Drugs industry.

Price-to-book value stands at 3.17, indicating a premium valuation on the company’s net assets. Enterprise value to EBIT and EBITDA ratios both sit at 10.52, suggesting that the market is pricing in reasonable earnings expectations. The PEG ratio is notably low at 0.06, signalling that the stock’s price growth has outpaced earnings growth, which may warrant caution.

Comparatively, peers such as NGL Fine Chem and Fredun Pharma trade at significantly higher PE ratios of 44.36 and 46.18 respectively, with correspondingly higher EV/EBITDA multiples, underscoring Unjha Formulations’ relatively fair valuation within its competitive set. The absence of a dividend yield further emphasises reliance on capital appreciation for investor returns.

Despite the fair valuation, the stock’s premium pricing relative to historical averages and peers suggests limited upside from a valuation perspective, justifying the cautious stance.

Financial Trend: Flat Quarterly Performance Amid Long-Term Strength

Financially, Unjha Formulations reported flat results in the quarter ended June 2026, with no significant growth in revenues or profits. This stagnation contrasts with the company’s longer-term trajectory, where profits have increased by 39% over the past year, supporting a 13.5% stock return in the same period.

Year-to-date, the stock has gained 8.6%, outperforming the Sensex which has declined by 7.84%. Over one month, the stock rose 11.82%, well ahead of the Sensex’s 1.25% gain. However, the past week saw a 5.57% decline in the stock price, slightly underperforming the Sensex’s flat movement.

These mixed short-term trends highlight volatility but also the stock’s capacity to deliver market-beating returns over extended periods. The company’s micro-cap status and non-institutional majority shareholding add layers of risk and potential illiquidity, which investors should weigh carefully.

Technicals: From Mildly Bearish to Sideways, Signalling Stabilisation

The most significant driver behind the upgrade to a Sell rating is the improvement in technical indicators. The technical trend has shifted from mildly bearish to sideways, suggesting a stabilisation in price action after a period of weakness.

Key technical signals include a bullish weekly MACD and Bollinger Bands, while monthly MACD remains mildly bearish but with bullish Bollinger Bands, indicating mixed but improving momentum. The daily moving averages are mildly bearish, reflecting some short-term caution.

The KST indicator is bullish on a weekly basis but bearish monthly, and the Dow Theory shows no clear trend on either timeframe. The Relative Strength Index (RSI) provides no definitive signals currently, neither weekly nor monthly.

Overall, these technical nuances suggest that while the stock is not yet in a strong uptrend, it has moved out of a downtrend and is consolidating, which supports a more positive near-term outlook compared to the previous strong sell stance.

Market Performance and Peer Comparison

Unjha Formulations has consistently outperformed the broader market indices over the medium to long term. Its 3-year return of 103.37% and 5-year return of 137.53% far exceed the Sensex’s respective returns of 19.57% and 43.97%. This outperformance is notable given the company’s micro-cap status and the inherent volatility associated with smaller stocks.

Within its sector, Unjha Formulations’ valuation remains fair relative to peers, many of whom trade at very expensive multiples. For instance, NGL Fine Chem and Hester Bios command PE ratios above 40, while Unjha’s 25.34 PE ratio offers a more reasonable entry point for investors seeking exposure to pharmaceuticals and biotechnology.

However, the company’s weak debt servicing ability and flat recent financial results temper enthusiasm, suggesting that while the stock is no longer a strong sell, it remains a cautious sell recommendation pending further fundamental improvement.

Conclusion: A Cautious Upgrade Reflecting Technical and Valuation Improvements

The upgrade of Unjha Formulations Ltd’s investment rating from Strong Sell to Sell is primarily driven by a stabilisation in technical indicators and a re-rating of valuation metrics from attractive to fair. While the company’s fundamental quality remains challenged by weak debt coverage and flat quarterly results, its long-term market-beating returns and reasonable valuation relative to peers provide some support.

Investors should remain vigilant given the stock’s micro-cap status, non-institutional majority ownership, and mixed technical signals. The current rating reflects a cautious optimism that the stock may be poised for consolidation or modest recovery, but significant fundamental risks persist.

Overall, Unjha Formulations presents a nuanced investment case where technical improvements and valuation adjustments have prompted a less negative outlook, yet fundamental weaknesses continue to warrant a conservative stance.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today